- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 16.06. | Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial | 140 | GlobeNewswire (Europe) |
-- Remains on track to release interim NF1 data update in Q4 2026 ---- Additional dose levels and longer treatment period added -- MIAMI, June 16, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp.... ► Artikel lesen | |
| 10.06. | Pasithea Therapeutics (KTTA) Could Find a Support Soon, Here's Why You Should Buy the Stock Now | 2 | Zacks | ||
| 02.06. | Pasithea receives orphan drug status for ALS treatment candidate | 1 | Investing.com | ||
| 02.06. | Pasithea Therapeutics Announces Orphan Drug Designation by FDA of PAS-004 for Treatment of Amyotrophic Lateral Sclerosis (ALS) | 159 | GlobeNewswire (Europe) | MIAMI, June 02, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 04.05. | Pasithea Therapeutics Corp. - 8-K, Current Report | - | SEC Filings | ||
| PASITHEA THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 04.05. | Pasithea Therapeutics appoints chief medical officer | 1 | Seeking Alpha | ||
| 04.05. | Pasithea names Kartik Krishnan as chief medical officer | 1 | Investing.com | ||
| 04.05. | Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer | 146 | GlobeNewswire (Europe) | MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 20.04. | FDA grants rare pediatric disease status to Pasithea's PAS-004 | 6 | Investing.com | ||
| 20.04. | Pasithea Therapeutics Announces Grant of Rare Pediatric Disease Designation (RPDD) by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) | 239 | GlobeNewswire (Europe) | MIAMI, April 20, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 01.04. | Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity | 144 | GlobeNewswire (Europe) | MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 20.02. | Pasithea Therapeutics Corp. - 8-K, Current Report | 4 | SEC Filings | ||
| 30.01. | Pasithea Therapeutics Corp. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 13.01. | Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines | 213 | GlobeNewswire (Europe) | MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation oral... ► Artikel lesen | |
| 21.11.25 | Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients | 352 | GlobeNewswire (Europe) | -- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with... ► Artikel lesen | |
| 20.11.25 | Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study | 253 | GlobeNewswire (Europe) | -- Evidence of Monotherapy Activity: Partial response observed in a MEK-rechallenge 3rd-line melanoma patient with BRAF V600E mutation who remains on trial for more than 11 months -- -- A second MEK-rechallenge... ► Artikel lesen | |
| 04.11.25 | Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 183 | GlobeNewswire (Europe) | MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 16.09.25 | Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients | 204 | GlobeNewswire (Europe) | MIAMI, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen | |
| 08.09.25 | Pasithea Therapeutics Announces Enrollment of Cohort 2 following Positive Safety Review Committee (SRC) Recommendation for its Ongoing Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 192 | GlobeNewswire (Europe) | -- Recommendation that trial escalate to next dose level of 8mg tablet -- -- Initial interim clinical data from first two cohorts expected in Q1 2026 -- MIAMI, Sept. 08, 2025 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 31.07.25 | Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients | 473 | GlobeNewswire (Europe) | MIAMI, July 31, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) ("Pasithea" or the "Company"), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic... ► Artikel lesen |
20 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVAVAX | 7,750 | -0,77 % | Novavax faces renewed attack by Shah Capital after AGM | ||
| PALATIN TECHNOLOGIES | 11,440 | 0,00 % | Palatin Technologies, Inc.: Palatin to Begin Trading on Nasdaq Stock Exchange | PRINCETON, N.J., May 18, 2026 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company focused on the discovery and development... ► Artikel lesen | |
| OCUGEN | 1,306 | +0,15 % | Ocugen Provides Business Update with First Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Positive 12-month data from the OCU410 Phase 2 ArMaDa clinical trial for geographic atrophy (GA) indicates a statistically significant (p About 20%... ► Artikel lesen | |
| ABIVAX | 84,15 | +4,08 % | Biotech Hoffnung erhält Dämpfer: Abivax Aktie stürzt nach Höhenflug ab Krebs Signale belasten Investmentstory | Die Abivax Aktie hat nach ihrem starken Höhenflug einen herben Rückschlag erlitten. Auslöser sind neue Sicherheitsfragen rund um den Hoffnungsträger Obefazimod. Obwohl der Wirkstoff in klinischen Studien... ► Artikel lesen | |
| NUREXONE BIOLOGIC | 0,349 | -3,86 % | NurExone bringt Entwicklung, Finanzierung und US-Ausbau voran | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,390 | -4,37 % | Druck auf Pacific Biosciences nimmt zu: Warum die Geduld der Anleger auf eine harte Probe gestellt wird | Pacific Biosciences gerät zunehmend unter Druck: Die Aktie steht nach einer "significant downward revision of revenue guidance" und dem erzwungenen Aktienrückzug eines Großaktionärs im Fokus. Für Investoren... ► Artikel lesen | |
| REDHILL BIOPHARMA | 0,892 | +1,53 % | RedHill Biopharma closes $6 million private placement | ||
| ONCO-INNOVATIONS | 0,460 | -2,23 % | Onco-Innovations stellt 300 g pharmazeutischen Wirkstoff für die Skalierung von ONC010 zur Unterstützung der für die IND-Zulassung erforderlichen Entwicklung her | Ernennung von Herrn Dave Antony zum CFO
Vancouver, Kanada - 19. Juni 2026 / IRW-Press / Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (FWB: W1H, WKN: A3EKSZ) ("Onco" oder... ► Artikel lesen | |
| NOVOCURE | 13,470 | 0,00 % | Novocure Announces Topline Data from the Phase 3 TRIDENT Trial Evaluating Earlier Use of Tumor Treating Fields Therapy in Newly Diagnosed Glioblastoma | The Phase 3 TRIDENT trial enrolled patients with glioblastoma prior to the initiation of chemoradiation and evaluated the benefit of initiating Tumor Treating Fields (TTFields) therapy at the start... ► Artikel lesen | |
| ADAPTIVE BIOTECHNOLOGIES | 18,180 | -1,25 % | Adaptive Biotechnologies Corp - 8-K, Current Report | ||
| PHARMING | 1,157 | +0,87 % | Pharming Group N.V.: Pharming announces U.S. FDA acceptance of sNDA resubmission for Joenja (leniolisib) to treat children aged 4 to 11 years with APDS | If approved, Joenja will be the first approved treatment in the U.S. for children with activated phosphoinositide 3-kinase delta (PI3Kd) syndrome (APDS), a rare primary immunodeficiency Supplemental... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 8,800 | +1,73 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| REVOLUTION MEDICINES | 160,00 | +0,03 % | Revolution Medicines, Inc.: Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic ... | REDWOOD CITY, Calif., June 23, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced... ► Artikel lesen | |
| ROCKET PHARMACEUTICALS | 2,870 | 0,00 % | Aktien New York: Weitere Verluste - Iran-Krieg und China-News belasten | NEW YORK (dpa-AFX) - Die US-Aktienmärkte haben am Freitag ihre Talfahrt fortgesetzt. Der anhaltende Iran-Krieg und die weiter steigenden Ölpreise mahnen die Anleger zur Vorsicht. Auf die Stimmung drückte... ► Artikel lesen | |
| GENPREX | 0,504 | +1,82 % | Genprex, Inc.: Genprex Receives a Notice of Allowance from The Canadian Intellectual Property Office for a Patent Claiming the Combination of Reqorsa Gene Therapy with Either PD-1 or PD-L1 Antibodies to Treat Cancer | Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentriq®
AUSTIN, Texas, June 22, 2026 /PRNewswire/ -- Genprex, Inc.... ► Artikel lesen |
Das Unternehmen PASITHEA THERAPEUTICS CORP kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,542 Euro und damit -0,20 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu PASITHEA THERAPEUTICS CORP finden Sie auf Wallstreet Online.